Pancreatic Cancer Research

ResearcherYokohama City UniversityActive in the last 2 years

Masaaki Murakawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6140-7953; OpenAlex author ID A5033251616. Sources: OpenAlex.

Their work

Papers
37 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
81
Papers, trials and grants by year

2014: 1 paper · 2015: 6 papers · 2016: 4 papers · 2017: 3 papers · 2018: 4 papers · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 5 papers · 2025: 3 papers · 2026: 3 papers

Papers 37

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geria… Co-author DOI 10.1093/jjco/hyag055↗
  3. Tissue Factor as a Prognostic and Therapeutic Biomarker in Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-026-19380-z↗
  4. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  5. Overexpression of Nuclear Factor of Activated T-cells (NFAT) Transcription Factors Drives Chemoresistance and Poor Outcomes in Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18186-9↗
  6. Significance of Preoperative Chemotherapy and Chemoradiotherapy in Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17804↗
  7. Clinical usefulness of C-reactive protein-albumin-lymphocyte (CALLY) index as a prognostic biomarker in patients undergoing surgical resection of pancreatic ca… Co-author DOI 10.1007/s00423-024-03512-8↗
  8. Prognostic nutritional index is an independent risk factor for continuing S-1 adjuvant chemotherapy in patients with pancreatic cancer who received neoadjuvant… Co-author DOI 10.1186/s12885-024-13244-z↗
  9. Clinical Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Surgical Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16805↗
  10. Clinical Impact of Preoperative Prognostic Nutritional Index in Surgical Patients With Pancreatic Cancer Treated With Perioperative Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16970↗
  11. Loss of Skeletal Muscle Mass During Neoadjuvant Chemotherapy for Pancreatic Cancer Is Related to the Continuation of S-1 Adjuvant Chemotherapy After Pancreatec… Co-author DOI 10.21873/anticanres.17286↗
  12. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. Co-author DOI 10.1186/s12957-023-03141-3↗
  13. Carbon Ion Radiotherapy Versus Perioperative Adjuvant Chemotherapy and Curative Surgery for Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16222↗
  14. Incidence and Risk of Venous Thromboembolism in Patients With Resectable Pancreatic Cancer Receiving Neoadjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.16327↗
  15. Postoperative acute pancreatitis after pancreatic resection in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-022-02481-0↗
  16. Clinical Implication of Pre-operative C-reactive Protein-Albumin Ratio as a Prognostic Factor of Patients With Pancreatic Ductal Adenocarcinoma: A Single-insti… Co-author DOI 10.21873/invivo.11780↗
  17. The Impact of Intraoperative Blood Loss on the Survival of Patients With Stage II/III Pancreatic Cancer. Co-author DOI 10.21873/invivo.11931↗
  18. The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuva… Co-author DOI 10.4103/jcrt.jcrt_440_18↗
  19. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Co-author DOI 10.7150/jca.28660↗
  20. The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant Chemotherapy. Co-author DOI 10.21873/anticanres.12801↗
  21. Safety and feasibility of enhanced recovery after surgery in the patients underwent distal pancreatectomy for pancreatic cancer. Co-author DOI 10.4103/0973-1482.183186↗
  22. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. Co-author DOI 10.4103/0973-1482.194927↗
  23. [Evaluation of Body Temperature during Pancreaticoduodenectomy for Pancreatic Cancer in Elderly Patients Aged over 75 Years Old]. Co-author PMID 29483421↗
  24. Clinical implications of ribonucleotide reductase subunit M1 in patients with pancreatic cancer who undergo curative resection followed by adjuvant chemotherap… Co-author DOI 10.3892/ol.2017.5935↗
  25. Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant … Co-author DOI 10.3892/ol.2017.6220↗
  26. Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemoth… Co-author DOI 10.3892/ol.2017.6295↗
  27. Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adju… Co-author PMID 26977002↗
  28. The Surgical Apgar Score Is an Independent Prognostic Factor in Patients with Pancreatic Cancer Undergoing Pancreatoduodenectomy Followed by Adjuvant Chemother… Co-author PMID 27127164↗
  29. [A Case of Pancreatic Cancer Associated with Autoimmune Pancreatitis]. First author PMID 27760963↗
  30. [Safety and Feasibility of Pancreatic Surgery for Pancreatic Cancer in Elderly Patients]. First author PMID 28133043↗
  31. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients. Co-author DOI 10.1007/s00280-015-2736-5↗
  32. Impact of postoperative complications on survival and recurrence in pancreatic cancer. First author PMID 25862906↗
  33. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemothe… Co-author PMID 25911897↗
  34. Lymphatic invasion is an independent prognostic factor in pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy with gemci… First author PMID 25916085↗
  35. Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery. First author PMID 26254380↗
  36. [The Safety and Feasibility of Conversion Surgery for Initially Unresectable Pancreatic Cancer]. Co-author PMID 26805070↗
  37. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer. Co-author DOI 10.1007/s00280-014-2601-y↗

Closest collaborators

The 25 strongest of 81 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 31 shared papers, 2014–2026 · strength 3.62
  2. Soichiro Morinaga · 34 shared papers, 2014–2026 · strength 3.51
  3. Naoto Yamamoto · 24 shared papers, 2014–2025 · strength 2.90
  4. Shinnosuke Kawahara · 11 shared papers, 2022–2026 · strength 1.95
  5. Satoshi Kobayashi · 17 shared papers, 2014–2026 · strength 1.84
  6. Toru Aoyama · 23 shared papers, 2014–2025 · strength 1.75
  7. Yuto Kamioka · 10 shared papers, 2020–2026 · strength 1.69
  8. Mariko Kamiya · 10 shared papers, 2018–2026 · strength 1.50
  9. Manabu Morimoto · 21 shared papers, 2014–2023 · strength 1.42
  10. Takashi Oshima · 13 shared papers, 2015–2024 · strength 1.10
  11. Hiroshi Tamagawa · 8 shared papers, 2018–2024 · strength 0.89
  12. Yohei Miyagi · 7 shared papers, 2016–2026 · strength 0.75
  13. Toru Aoyama · 5 shared papers, 2016–2024 · strength 0.74
  14. Kota Washimi · 3 shared papers, 2016–2026 · strength 0.49
  15. Keiko Kamei · 2 shared papers, 2026 · strength 0.38
  16. Michiaki Unno · 2 shared papers, 2026 · strength 0.38
  17. Tsutomu Fujii · 2 shared papers, 2026 · strength 0.38
  18. Masakatsu Numata · 4 shared papers, 2018–2020 · strength 0.34
  19. Shiro Koizume · 1 shared paper, 2026 · strength 0.24
  20. Yuichiro Tozuka · 1 shared paper, 2025 · strength 0.22
  21. Junji Furuse · 1 shared paper, 2025 · strength 0.22
  22. Shun Tezuka · 1 shared paper, 2025 · strength 0.22
  23. Shin Maeda · 1 shared paper, 2025 · strength 0.22
  24. Yukihiko Hiroshima · 1 shared paper, 2025 · strength 0.20
  25. Robert M. Hoffman · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.